Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment

Evangelos Terpos, Efstathios Kastritis, Argiris Symeonidis, Anastasia Pouli, Sosana Delimpasi, Eirini Katodritou, Eleftheria Hatzimichael, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Kyriaki Manousou, Maria Gavriatopoulou, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 6712.

https://doi.org/10.1182/blood-2023-173185

Published: 2023

Journal Articles

A Phase II Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Progressing on or after One Line of Lenalidomide-Containing Therapy

Evangelos Terpos, Maria Gavriatopoulou, Eirini Katodritou, Argiris Symeonidis, Anastasia Pouli, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Ioannis Ninos, Sosana Delimpasi, Eleftheria Hatzimichael, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 6728.

https://doi.org/10.1182/blood-2023-173170

Published: 2023

Journal Articles

Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT

Blood (2022) 140 (Supplement 1): 900–902.

https://doi.org/10.1182/blood-2022-160121

Published: 2022

Journal Articles

Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-138390

Published: 2020

Journal Articles

The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome

Panagiotis T Diamantopoulos, MD PhD, Vassiliki Pappa, MD, Nora-Athina Viniou, MD PhD, Ioannis Kotsianidis, Alexandra Kourakli, MD PhD, Argiris Symeonidis, MD PhD, Sotirios Papageorgiou, MD PhD, Elena E. Solomou, MD, Anastasia Pouli, MD PhD, Panagiotis Panagiotidis, MD PhD, Maria Dimou, MD PhD, Kalliopi Zafeiropoulou, Stamatis J. Karakatsanis, MD MSc, Anna Vardi, MD PhD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Tsokanas, George Drakos, Spyros Hontropoulos, Eleftheria Hatzimichael, Aikaterini Megalakaki, Panagiotis Repousis, MD, Maria Kotsopoulou, Georgia Kaiafa, MD, Menelaos Konstantinos Papoutselis, Anastasia Sioni, Nikolaos Charchalakis, PhD, Eleni Bouronikou, Georgios Vasilopoulos, Vasileios Lazaris, Maria Spiliotopoulou, Flora Kontopidou, Christos K. Kontos, PhD, Stamatina Kalyva, Apostolos Hatzitolios, Helen A. Papadaki, MD PhD, Achilles Anagnostopoulos, Nikolaos Anagnostopoulos, Athanasios Galanopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5427.

https://doi.org/10.1182/blood-2019-127417

Published: 2019

Journal Articles

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Argiris Symeonidis, MD PhD, Sotirios Papageorgiou, MD PhD, Antonis Patrinos, MD, Maria Melachrinou, MD PhD, Alexandra Kourakli, MD PhD, Vassiliki Pappa, MD, Maria K. Angelopoulou, MD, Anastasia Sioni, Nikolaos Kanellias, MD, Sofia Chatzileontiadou, MD, Eleftheria Hatzimichael, Panagiotis Zikos, Anastasia Pouli, MD PhD, Maria Papaioannou, Evangelos Terpos, MD PhD, Gerasimos Pangalis, MD, Theodoros P. Vassilakopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5340.

https://doi.org/10.1182/blood-2019-130219

Published: 2019

Journal Articles

Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group

Blood (2018) 132 (Supplement 1): 3295.

https://doi.org/10.1182/blood-2018-99-114106

Published: 2018

Journal Articles

Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients

Blood (2018) 132 (Supplement 1): 1966.

https://doi.org/10.1182/blood-2018-99-112851

Published: 2018

Journal Articles

Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group

Blood (2018) 132 (Supplement 1): 1978.

https://doi.org/10.1182/blood-2018-99-115725

Published: 2018

Journal Articles

Characteristics and Outcome of Multiple Myeloma Patients Presenting with Anemia Only: a Retrospective Multi-Center Study

Tamir Shragai, MD, Moshe E. Gatt, MD, Adir Shaulov, MD, Eirini Katodritou, MD, Theodora Triantafyllou, MD, Noa Lavi, MD, Anastasia Pouli, MD PhD, Anastasia Sioni, Iuliana Vaxman, MD BA, Miri Zektser, MD, Chezi Ganzel, MD, Noam Benyamini, MD, Svetlana Trestman, MD, Tomer ziv Baran, PhD, Yael C Cohen, MD, Irit Avivi, MD

Blood (2018) 132 (Supplement 1): 5578.

https://doi.org/10.1182/blood-2018-99-116372

Published: 2018

Journal Articles

Prognosis of Lower Risk Patients with Myelodysplastic Syndromes without Isolated Del(5q) after Failure of Erythropoiesis-Stimulating Agents. a Multicenter Study By the Hellenic MDS Study Group

Athanasios G. Galanopoulos, MD PhD, Christos K. Kontos, PhD, Argiris Symeonidis, MD PhD, Ioannis Kotsianidis, MD PhD, Alexandra Kourakli, MD, Vassiliki Pappa, MD, Thomas Tsiambalis, Anastasia Pouli, MDPhD, Panayiotis Panayiotidis, MD PhD, Paraskevi Roussou, Stamatis Karakatsanis, Kalliopi Zafeiropoulou, Maria Dimou, Theodoros P. Vassilakopoulos, MD PhD, Anna Vardi, MD PhD, Dimitrios Tsokanas, George Drakos, Eleftheria Hatzimichael, Aikaterini Megalakaki, Panagiotis Repousis, MD, Maria Kotsopoulou, Elena E. Solomou, MD PhD, Georgia Kaiafa, Menelaos Konstantinos Papoutselis, Anastasia Sioni, Nikolaos Charchalakis, PhD, Eleni Bouronikou, George Vassilopoulos, MD PhD, Vasileios Lazaris, Athanasios Galanopoulos, MD PhD, Panagiotis Theodorou Diamantopoulos, MD PhD, Flora Kontopidou, Zoi Topouzoglou, Stamatina Kalyva, Helen A. Papadaki, MD PhD, Apostolos Hatzitolios, Achilles Anagnostopoulos, Nikolaos Anagnostopoulos, Nora-Athina Viniou

Blood (2017) 130 (Supplement 1): 2979.

https://doi.org/10.1182/blood.V130.Suppl_1.2979.2979

Published: 2017

Journal Articles

Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death

Blood (2016) 128 (22): 2954.

https://doi.org/10.1182/blood.V128.22.2954.2954

Published: 2016

Journal Articles

Validation of the Revised International Prognostic Scoring System in 2582 Patients with Myelodysplastic Syndrome: A Multicenter Study By the Hellenic MDS Study Group

Athanasios Galanopoulos, MD PhD, Christos K. Kontos, Nora-Athina Viniou, MD PhD, Ioannis Kotsianidis, MD PhD, Vassiliki Pappa, MD PhD, Aleka Kourakli, MD PhD, Anastasia Pouli, Panayiotis Panayiotidis, MD PhD, Paraskevi Roussou, MD PhD, Kalliopi Zafeiropoulou, Stamatis Karakatsanis, Maria Dimou, Anna Vardi, Theodoros Vassilakopoulos, MD PhD, Dimitris Tsokanas, Eleftheria Hatzimichael, MD PhD, Aikaterini Megalakaki, MD, Georgia D Kaiafa, MD PhD, Menelaos Konstantinos Papoutselis, Anastasia Sioni, Nikolaos Charchalakis, MD PhD, Eleni Bouronikou, MD PhD, George Vassilopoulos, MD PhD, Vasilios Lazaris, Maria Spiliotopoulou, Panagiotis Theodorou Diamantopoulos, Flora Kontopidou, MD PhD, Zoi Topouzoglou, Stamatina Kalyva, Helen A. Papadaki, MD PhD, Apostolos I Hatzitolios, Professor of Internal MDcine, Achilles Anagnostopoulos, MD, Evangelos Briasoulis, MD PhD, Nikolaos I. Anagnostopoulos, MD, Argiris S. Symeonidis, MD PhD

Blood (2016) 128 (22): 2004.

https://doi.org/10.1182/blood.V128.22.2004.2004

Published: 2016

Journal Articles

Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients

Blood (2014) 124 (21): 2113.

https://doi.org/10.1182/blood.V124.21.2113.2113

Published: 2014

Journal Articles

No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience

Blood (2014) 124 (21): 4752.

https://doi.org/10.1182/blood.V124.21.4752.4752

Published: 2014

Journal Articles

Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?

Blood (2013) 122 (21): 1866.

https://doi.org/10.1182/blood.V122.21.1866.1866

Published: 2013

Journal Articles

Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients

Meletios A. Dimopoulos, MD, Evangelos Terpos, Argiris S. Symeonidis, Eirini Katodritou, Anastasia Pouli, Sosana Delimpasi, Kostas Konstantopoulos, Michalis Michael, Eleftheria Hatzimichael, Maria Kotsopoulou, Dimitra Gika, Maria Roussou, Stavroula Giannouli, Costas Tsatalas, Efstathios Kastritis

Blood (2013) 122 (21): 1867.

https://doi.org/10.1182/blood.V122.21.1867.1867

Published: 2013

Journal Articles

Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients

Blood (2013) 122 (21): 3130.

https://doi.org/10.1182/blood.V122.21.3130.3130

Published: 2013

Journal Articles

Greek Registry Of Essential Thrombocythemia: Baseline Characteristics and Therapeutic Strategy

Blood (2013) 122 (21): 4084.

https://doi.org/10.1182/blood.V122.21.4084.4084

Published: 2013

Journal Articles

The Chronic Kidney Disease-Epidemiology Collaboration-Cystatin C (CKD-EPI-CysC) Equation Has an Independent Prognostic Value for Overall Survival in Newly-Diagnosed Patients with Symptomatic Multiple Myeloma: Comparison with 3 Other Equations for GFR Estimation

Meletios A Dimopoulos, MD, Efstathios Kastritis, Eirini Katodritou, Anastasia Pouli, Eurydiki Michalis, Dimitrios Christoulas, Maria Gkotzamanidou, Ioannis Papassotiriou, Konstantinos Zervas, Evangelos Terpos

Blood (2012) 120 (21): 1849.

https://doi.org/10.1182/blood.V120.21.1849.1849

Published: 2012

NARROW

A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment

A Phase II Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Progressing on or after One Line of Lenalidomide-Containing Therapy

Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT

Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study

The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group

Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients

Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group

Characteristics and Outcome of Multiple Myeloma Patients Presenting with Anemia Only: a Retrospective Multi-Center Study

Prognosis of Lower Risk Patients with Myelodysplastic Syndromes without Isolated Del(5q) after Failure of Erythropoiesis-Stimulating Agents. a Multicenter Study By the Hellenic MDS Study Group

Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death

Validation of the Revised International Prognostic Scoring System in 2582 Patients with Myelodysplastic Syndrome: A Multicenter Study By the Hellenic MDS Study Group

Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients

No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience

Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?

Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients

Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients

Greek Registry Of Essential Thrombocythemia: Baseline Characteristics and Therapeutic Strategy

The Chronic Kidney Disease-Epidemiology Collaboration-Cystatin C (CKD-EPI-CysC) Equation Has an Independent Prognostic Value for Overall Survival in Newly-Diagnosed Patients with Symptomatic Multiple Myeloma: Comparison with 3 Other Equations for GFR Estimation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only